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Abstract
Papillomaviruses (PVs) are established agents of human and animal cancers. They infect cutaneous and mucous
epithelia. High Risk (HR) Human PVs (HPVs) are consistently associated with cancer of the uterine cervix, but are
also involved in the etiopathogenesis of other cancer types. The early oncoproteins of PVs: E5, E6 and E7 are
known to contribute to tumour progression. While the oncogenic activities of E6 and E7 are well characterised, the
role of E5 is still rather nebulous. The widespread causal association of PVs with cancer makes their study
worthwhile not only in humans but also in animal model systems. The Bovine PV (BPV) system has been the most
useful animal model in understanding the oncogenic potential of PVs due to the pivotal role of its E5 oncoprotein
in cell transformation. This review will highlight the differences between HPV-16 E5 (16E5) and E5 from other PVs,
primarily from BPV. It will discuss the targeting of E5 as a possible therapeutic agent.
Keywords: Cell transformation, Growth factor receptors, Immune escape, Oncogene, Papillomaviruses, E5 oncopro-
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Introduction
PVs are established agents of human and animal cancers
[1]. They infect cutaneous and mucous epithelia indu-
cing benign tumours which usually regress. Occasion-
ally, the tumours progress to malignancy. Over 120
types of HPVs have been identified so far and among
these 15 have been defined as HR HPVs. These are con-
sistently associated with cancer. Genital HPVs are sexu-
ally transmitted and HR genital HPVs are a necessary
factor in the development of almost all cases of cervical
cancer. HPV-16 and -18 are the viruses most frequently
associated with cancer of the uterine cervix (CxCa) [2].
CxCa is the second most common cancer in women
worldwide killing about 0.25 million women per year.
However, in economically developed countries the rate
of CxCa is dramatically reduced due to screening pro-
gram based on exfoliative cervical cytology (PAP
smears).Vaccines to prevent HR HPV infection are avail-
able, although their use should be implemented along
with screening programmes to further reduce the
incidence of such cancer [3]. HR HPVs are also involved
in the etiopathogenesis of other anogenital cancer [4].
Furthermore HPV, particularly HR HPV-16 is strongly
associated to oral squamous cell carcinoma and other
potentially malignant oral lesions [5]. Growing evidence
also suggests that HR HPV-16 is involved in the etio-
pathogenesis of head and neck squamous cell carcino-
mas, suggesting that HPV vaccines should be also
considered for prevention of this type of cancer [5,6].
Additionally, HPVs may be involved in the etiopatho-
genesis of others cancer types, including tumours of the
upper respiratory tract, eye, esophagus, non-small-cell
lung cancers [7-10]. The presence of HPV-16 has been
reported also in colorectal carcinoma [11], breast cancer
[12] and urinary bladder carcinoma [13]. Recently, HPV
DNA has been associated also with prostatic tumours
[14]. The widespread causal association of PVs with can-
cer makes their study worthwhile not only in humans
but also in animal model systems which often provide
new and profitable avenues of research [15]. The BPV
system has been one of the most useful animal models
in understanding the oncogenic potential of PVs.
Furthermore, the mechanisms by which BPV induces
tumors are an outstanding model to better understand
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the pathogenesis of other cancer types. The importance
of the role of HPV in cancer etiology and development
has been recognized by the assignment of the 2008
Nobel Prize for Medicine to Prof. Harald zur Hausen
who firstly observed that infection with HPVs is respon-
sible for CxCa development. The genome of PVs is a
double stranded circular DNA roughly divided into
three parts: the E region coding for early proteins (E1-
E7) responsible for the pathogenicity of the virus; the L
region coding for late structural proteins (L1, L2) and a
non coding region which contains the cis-elements
necessary for replication and transcription of the viral
genome. Both in vivo and in vitro studies have pointed
to E6 and E7 as the main HPV oncogenes, whereas E5
is the major oncogene of BPV. The E6 oncoprotein
interacts with the cellular tumour suppressor p53 [16]
and directs its degradation [17]. The primary target of
the E7 oncoprotein is the retinoblastoma (Rb) proteins,
the inactivation of which leads to tumour progression
[18]. Both E6 and E7 also interact with many others cel-
lular factors inducing genomic instability, tumour pro-
gression and immune evasion [18].
While the oncogenic activities of E6 and E7 are well
characterised, the role of E5 is still rather nebulous.
However, recent studies have highlighted the important
role of this oncoprotein in cell transformation, tumouri-
genesis and immune modulation, thus implicating E5 in
pivotal steps of carcinogenesis. Because of the perceived
growing role of E5 in infection establishment and in cell
transformation, it is worth considering the most salient
features of the oncoprotein. This review will focus on
the activities of E5, in particular from HPV-16, and
from BPV. Targeting E5 as a possible therapeutic agent
will also be briefly discussed.
HPV E5
E5 and the evolution of HPVs
HPVs have been classified into five genera (Alpha-, Beta-,
Gamma-, Mu- and Nu-PVs), but not all HPV genera code
for an E5 protein [19]. For instance aHPVs encode and
express E5 but b HPVs do not. A phylogenetic analysis of
known genital HPV types (derived using a Bayesian meth-
odology, with notation of carcinogenic risk levels assigned
by the large case-control study conducted by the Interna-
tional Agency for Research on Cancer [20]), suggested
that at least 3 ancestral papillomaviruses are responsible
for the current heterogeneous group of genital HPVs. The
three major groups that emerged include alpha papilloma-
virus species and interestingly all carcinogenic types derive
from a common ancestor and can code for an E5 protein,
whereas the other HPVs either lack a definable E5 ORF
(Open Reading Frame) or a translation start codon for E5.
As notable exceptions, 10 types which cause benign vener-
eal warts, can also code for an E5 protein. In addition,
16E5 variants with the greatest mitogenic activity in vitro
[21] are most frequently detected in the population and
most commonly associated with cervical lesions.
The HPV E5 ORF itself has been classified into four dif-
ferent groups: alpha, beta, gamma and delta [22], which
correlate with different clinical manifestations, in particu-
lar with oncogenic potential [23]. Thus, the E5-alpha pro-
tein is encoded by HR aHPV, whereas the E5-gamma and
E5-delta proteins are encoded by low-risk genital HPVs
[24]. The phylogenetic analysis suggests that E5 must give
some advantage to the virus expressing it and variants of
this protein appear to increase the likelihood of oncogenic
transformation following persistent infections. However,
the E5 ORF is absent in the genome of many HPVs, such
as beta-, gamma- and mu-HPVs, indicating that the pro-
tein is not essential for the life cycle of these viruses but
rather can give some ADDED VALUE to favour infection
and transformation (Figure 1). The HPV E5 ORF is
expressed during the early phases of the viral life cycle but
only as the fourth ORFs on polycistronic transcripts. Since
HPVs are thought to use a leaky ribosome-scanning
mechanism to translate proteins from polycistronic
mRNAs, little E5 protein is likely to be synthesized from
these transcripts. In contrast, on epithelial-cell differentia-
tion, E5 is expressed as the second ORFs of late tran-
scripts. It is therefore likely that E5 is synthesized highly in
differentiating suprabasal epithelial cells [25] (Figure 1). In
agreement, the BPV-1 E5 protein was detected at a low
uniform level in basal layers and at a higher level in the
uppermost layers of stratified squamous epithelium in
papillomas productively replicating BPV-1 [26]. In addi-
tion, E5 was also shown to be expressed in basal and
suprabasal layers of BPV4-induced papillomas [27] and of
HPV-16 induced cervix lesions [28].
In contrast to the highly transforming BPV-1 E5, the
HPV E5 proteins display weak transforming activity in
vitro (Table 1). Experiments with HPV-6 provided the
first evidence that a HPV E5 protein had transforming
activity in mammalian cells, as expression of HPV-6 E5
in established murine fibroblasts lead to anchorage inde-
pendent growth [29]. Later it was shown that also 16E5
induces anchorage independence, more efficient growth
in low serum and tumorigenic transformation of murine
keratinocytes and fibroblasts [30-32]. In addition, the
acute expression of 16E5 stimulates cellular DNA synth-
esis in primary human keratinocytes, and in cooperation
with E7, induces proliferation of primary rodent cells
[33-36]. The transforming activity of E5 from HPV-59
and rhesus papillomavirus has been demonstrated in
various cell types and assays [37,38].
Structure and cell interaction
16E5 is 83 amino acid long. The detection of this pro-
tein has proved very difficult given its extreme
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hydrophobicity, membrane localisation and very low
levels of expression. For these reasons expression of E5
is often inferred from the presence of E5 mRNA. 16E5
has been detected by immunohistochemistry by Chang
et al. [28] in low-grade squamous intraepithelial lesions
(LSILs), in high-grade SILs, CIN (cervical intraepithelial
neoplasia) and paradoxically in cancer lesions although
often this gene is deleted during viral integration into
the host genome. Amino acid sequence analyses of 16E5
suggest it comprises 3 anchor-like a-helices (residues 8-
30, 37-52 and 58-76), with only the first being long
enough to span a lipid bilayer.
When over-expressed, 16E5 is present in the endo-
plasmic reticulum (ER), in the nuclear envelope and in
the Golgi apparatus (GA) [39], whereas at a more phy-
siological level of expression, as shown in primary
human foreskin keratinocytes, it localizes almost exclu-
sively to the ER and to lesser extent to GA and early
endosomes [40]. Recently, it was reported that in
HaCaT cells about 10% of total 16E5 can localize to
plasma membrane with intracellular amino terminus
and extracellular carboxyl-terminus. This observation
suggests a fusogenic role of 16E5 with the induction of
cell-cell fusion and the formation of binucleated HaCaT
cells [41-43]. In contrast, other authors report the pre-
sence of 16E5 protein only in the ER of COS and ecto-
cervical cells in the opposite orientation: intraluminal
amino-terminus and cytoplasmic carboxyl-terminus [44].
The cytoplasmic localization of the C terminus is further
strengthened by the reported interaction of 10 amino
acids at the C terminus of 16E5 with karyopherin b3
(KNb3) [45], an abundant cellular protein localized
mainly in the cytoplasm [46,47]. An explanation for
these contrasting data is the possible presence of 16E5
in the plasma membrane as a consequence of the over-
expression of 16E5 by the adenovirus vector system
used in HaCaT cells. In agreement, when BPV-1 E5 is
expressed at very high levels, such as in baculovirus-
infected cells, it is detectable on the plasma membrane
in addition to the ER and GA [48].
16E5 self-associates in vitro [49] and in vivo [40,50]
and this oligomerization takes part mostly by hydropho-
bic interaction. The reported disulfide bonding [40]
appears less likely because models of 16E5 membrane
topology predict the localization of all six cysteine resi-
dues within the lipid bilayer [21,51] rendering cysteine
dimerization more difficult.
E5 and cell transformation
E5 interacts with a number of cellular proteins and
these interactions are deemed important for the biologi-
cal activity of the protein in cell transformation and eva-
sion of the immune response. Thus the first
transmembrane domain of 16E5 and HPV-31E5 inter-
acts directly with the heavy chain component of the
MHC I (Major Histocompatibility Complex class I) via
the leucine pairs present in this region; interestingly this
same transmembrane domain interacts with a chaperone
Figure 1 E5 can improve HPV activity by altering host factors controlling the viral replication/persistence. A schematic view of the
papillomavirus life cycle highlighting the expression of the HPV genes, which is tightly regulated and strictly linked to epithelial differentiation.
E5 could contribute to a successful infection by inducing loss of surface MHC I expression in the infected basal cells preventing presentation of
viral antigens to effector T-cells and thus, in addition to other mechanisms of immune avoidance, such as lack of inflammation, contributing to
evasion of immune surveillance. Expression of E5 in the basal/suprabasal layers of the epithelium would lead to sustained cell proliferation to
favour virus-infected cells, but extinction of its expression in the more superficial layers would permit cell differentiation and virion production. If
E5 expression proceeds beyond early lesional stages, keratinocyte differentiation and immunological removal of infected cells would not take
place and the lesion would be at greater risk for neoplastic progression. E5 actions on host factors controlling viral replication/persistence are
indicated. Dashed dots indicate low levels of E5 gene expression.
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of MHC I, Bap31 [52,53]. A region within the second
helix (residues 41-54) may be the binding site for the 16
kDa pore sub-unit of vacuolar-ATPase (V-ATPase) [54],
although others claim this is located between residues
54-78 [55].
E5 is a weak transforming protein in vitro and its
effects are seen best when in co-operation with the
other viral oncoproteins: 16E5 together with E6 can
induce the formation of koilocytes, large cells with
cleared cytoplasm and pyknotic nuclei with inconspicu-
ous nucleoli, a well known morphological marker of
HPV infection [56]. The development of koilocytotic
vacuoles may be linked to the E5-induced relocalization
of calpactin I to the perinuclear region promoting peri-
nuclear membrane fusion [57]. Hu et al. [43] confirmed
previous reports describing the oncogenic capacity of
16E5 [30,58] and offered mechanistic insights into how
E5 expression brings about morphological changes in
the cervical epithelium. Further, by identifying endore-
plication as the mechanism by which the aberrant nuclei
form and increased DNA synthesis arises, there is now a
biological process that can be targeted to inhibit onco-
genesis [43]. Fusogenic 16E5 is expressed on the plasma
membrane of cells and both cells must express E5 for
cell-cell fusion to occur, indicating that E5 cannot
induce cell-cell fusion through an interaction with
another protein (receptor) on a neighbouring cell, but
rather forms E5-E5 dimers or complexes containing at
least two 16E5 molecules. These findings provide impor-
tant insight into how the fusogenic process is mediated
[41].
E5 of HR HPV by itself can induce morphological and
chromosomal changes that frequently accompany the
progression of normal cells to cancerous cells. Increased
nuclear size, increased DNA content and tetraploidy are
characteristic of LSIL [59,60]. All of these morphological
changes have been detected in cell expressing 16E5 and,
in particular, the aberrant nuclei formation seems to be
due to endoreplication rather than a consequence of
cell-cell fusion and failed cytokinesis [43]. Many of these
changes are criteria used in the clinical detection of cer-
vical cancer precursors in screening Pap tests [61].
Other morphological changes, such as the presence of
binucleated cells, increased DNA content and polyploidy
[62], are not used in the diagnosis of precancerous
lesions despite being less subjective because they require
larger amounts of material, time, and expenses.
HPV E5 interaction with host cell
HPVs infect stratified epithelia, and their whole life
cycle is inextricably linked to keratinocyte differentiation
and, in order to establish a persistent infection, HPVs
have evolved to overcome many “obstacles":
a) The stratified epithelium is associated with continu-
ous cellular turnover and desquamation of the termin-
ally differentiated keratinocytes, thus maintenance of the
papillomavirus within the tissue requires the infection of
basal epithelial cells and the propagation of these
infected cells.
b) Papillomaviruses use the cellular machinery for
their replication and need to maintain cell division
together with a delayed but not completely inhibited dif-
ferentiation. HPV infected keratinocytes with imbal-
anced DNA synthesis/differentiation are forced to
apoptosis by the cellular control mechanism.
c) To establish persistent infection HPV must fight or
evade immune-surveillance.
It is clear that the timely and epithelial differentiation-
dependent expression of all E proteins is essential to
favour viral replication and in turn to overcome the
above mentioned obstacles. The “E5 added value” will
be highlighted in the following paragraphs.
E5, growth factors and cell cycling
HPV infection is thought to take place when epithelial
basal cells are directly exposed to the virus during
microinjuries [63]. Infection of epithelial stem cells,
which have the capacity for self-renewal, can ensure
Table 1 Comparison of function of HPV E5 proteins with
BPV E5 proteins
E5 LR HPV-6 HR HPV-16 BPV-1 BPV-4
FF n.e. - + +
SI n.e. + + +
AI + + + +
Koilocytosis + + n.e. n.e.
PDGFbR activation n.e. - + n.e.
EGF-R activation + + + n.e.
V-ATPase binding + + + +
Gap-j inhibition n.e. + + +
PI3-K activation n.e. + + n.e.
c-Src activation - - + +
Cyclin-cdk2 activation n.e. + + ++
MHC I down-regulation + + + +
KNb3 binding n.e. + n.e. n.e.
TRAIL pathway inhibition n.e. + n.e. n.e.
MAPK activation + + - n.e.
ETA activation n.e. + n.e. n.e.
PGE2 R expression n.e. + n.e. n.e.
Cellular zinc imbalance n.e. + n.e. n.e.
ER Stress pathway inhibition - + n.e. n.e.
Cellular fusion - + n.e. n.e.
P21 inibition + + n.e. n.e.
FF: focus formation; SI: serum independence; AI: anchorage independence. +:
presence of function; -: absence of function; n.e.: not established.
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long term maintenance of the viral genome. During the
productive stage of the HPV life cycle, the early viral
proteins are expressed, maintaining 50-100 copies of
episomal DNA per cell by synchronous replication with
host cell DNA [64-66]. The demonstrated ability of
16E5 to enhance ligand-dependent activation of the
EGF-R [56,58-60] (Figure 2) and to stimulate EGF-
dependent proliferation of cultured human keratinocytes
[33,35,58] suggests that 16 E5 may play a major role in
expanding populations of HPV-16-infected basal kerati-
nocytes in vivo by enhancing ligand-dependent EGF-R
activation. Confirmation of this E5 activity comes from
a study on 16E5 transgenic mice showing that functional
EGF-R is required for the induction of epidermal hyper-
plasia and formation of spontaneous skin tumours [67].
16E5 oncoprotein binds and inhibits the activity of the
16 kDa subunit of V-ATPase, altering the endosomal
acidification and degradation of EGF-R [34,68] thus
enhancing its recycling to the plasma membrane. 16E5
can also delay EGF-R degradation by interfering with
membrane trafficking and the fusion of early and late
endosomes [69]. Recently, 16E5 was shown to form a
complex with KNb3 which is localized mainly in the
cytoplasm near the nuclear envelope [45]. It has been
suggested that a KNb3/16E5 complex plays an impor-
tant role in vesicle trafficking, reinforcing the hypothesis
that E5 has a central role in altering protein trafficking
inside the cell. The EGF-R signalling pathway can be
activated by 16E5 through either EGF-dependent or
EGF-independent processes. 16E5 activates mitogen-
activated protein kinase (MAPK) p38 and ERK1/2 in
human keratinocytes in an EGF-independent manner
[70]. Two different pathways, a receptor tyrosin kinase-
mediated pathway and a protein kinase C (PKC)-depen-
dent pathway, are involved in the MAPK activation
[71,72] which increases the transcription of c-fos and c-
jun [33,73,74], forcing the cells through the cell cycle
and stimulating transcription of the viral oncogenes E6
and E7. In contrast with EGF-R data, less is know about
the role of the interaction of 16E5 with other ErbB
family members such as ErbB2 or ErbB4 receptor
[28,75-77].
Figure 2 HPV 16 E5 enhances growth factor signalling pathways. Activation of EGF-R and the downstream Ras-Raf-MAP kinase pathway or
PI3K-Akt pathway leads to altered cell proliferation, angiogenesis, and anti-apoptosis. The last two functions are further enhanced by the E5-
induced upregulation of COX-2 expression. COX-2 expression inhibits hydrogen peroxide-induced apoptosis and induces PGE2 secretion that
activates EP4 receptor. This, in turn, causes cAMP production, activating PKA; PKA contributes to E5-induced expression of EP4 by enhancing
CREB binding to variant CRE of the EP4 promoter. PKA influences also apoptosis through the ubiquitin-proteasome degradation of BAX. Finally,
E5 protein enhances cell proliferation through downregulation of tumor suppressor p21/p27 and through up-regulation of G protein-coupled
endothelin receptor (ETA)/ET1 autocrine loop. Dotted arrow shafts indicate uncertain pathways. The possible cross-talking between ETAR and
EGFR pathway through Src protein is also indicated.
Venuti et al. Molecular Cancer 2011, 10:140
http://www.molecular-cancer.com/content/10/1/140
Page 5 of 18
16E5 is also capable of interacting with, and enhan-
cing the signalling of, different classes of growth factor
receptors like the G protein-coupled endothelin receptor
(ETA) [36]. In growth factor-starved keratinocytes 16E5
enhances the mitogenic activity of endothelin-1 (ET-1)
the specific ligand of ETA (Figure 2). Interestingly it was
reported that the mitogenic activity of ET-1 may lead to
the chronic stimulation of keratinocyte proliferation
observed in psoriasis, an inflammatory/proliferative dis-
order of the skin, suggesting an important role for ET-1
in epithelial proliferation [78]. Furthermore cross-talking
between ETAR and EGF-R pathways would have an
amplifying effect on cell proliferation [79].
In contrast to the activation of EGF-R, 16E5 can
down-modulate the keratinocyte growth factor receptor/
fibroblast growth factor receptor 2b (KGF-R/FGF-R2b),
through reduction of transcripts and protein with altera-
tion of the receptor endocytic trafficking. This causes a
decrease in the growth response to the receptor ligands,
suggesting that 16E5 might have a role on HPV infec-
tion by perturbing the KGFR-mediated physiological
behaviour of confluent keratinocytes committed to dif-
ferentiation [80]. Thus, 16E5 could exert two opposite
effects, both related to virus replication: (a) increasing
the growth of the most basal undifferentiated cells by
up-regulating the EGF-R pathway and (b) decreasing the
physiological proliferation/differentiation of the supraba-
sal keratinocytes by down-modulation of KGFR expres-
sion and signalling.
16E5 can also down-regulate the expression of tumour
suppressor p21 and p27, both of which are cyclin-
dependent protein kinase inhibitors (CKIs), thus causing
cell cycle progression and DNA synthesis (S-phase) (Fig-
ure 2). The p21Wafl/Sdil/Cipl down-regulation is at tran-
scriptional level [81] whereas that of p27Kip1, one of the
most abundant CKIs, is through reduction of the half-
life of p27Kip1 protein [82].
Other biological activities of 16E5 contribute to the
proliferation of the infected cells, such as the interfer-
ence with cell-cell communication and alteration of
adherence and cell motility. The ability of 16E5 to inhi-
bit gap junction-mediated communication between
epithelial cells in monolayer [83] and in raft cultures
[84] by interfering with connexin 43 may render the
transformed cells more insensitive to homeostatic
growth control signals from adjacent normal cells.
E5 and apoptosis
Due to the integration of HR HPV genome during
malignant progression, the E5 gene is not expressed in
cervical tumours but both 16/18 E5 mRNA and protein
have been detected in anogenital LSIL [85,86] support-
ing the possibility that E5 plays a role in early steps of
HPV infection to protect infected cells from apoptosis.
Indeed, it has been proposed that inhibition of death
receptor-mediated apoptosis in human keratinocytes,
needed to prevent apoptosis at early stages of viral infec-
tion, is a primary function of the HR HPV E5 protein.
16E5 impairs tumor necrosis factor ligand (FasL) and
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)-mediated apoptosis in HaCaT cells by: (a)
downregulating the total amount of Fas receptor and
reducing Fas surface location; and (b) altering the for-
mation of Death-Inducing Signalling Complex (DISC)
triggered by TRAIL [87]. Raft cultures of 16E5-expres-
sing keratinocytes were completely protected from FasL-
or TRAIL-induced cell death [88]. Likewise, when UV
radiation was used to induce stress, E5-expressing
human keratinocytes were protected from apoptosis
[89]. In contrast, 16E5 sensitizes human keratinocytes to
apoptosis induced by osmotic stress, perhaps due to cell
membrane modifications caused by this strongly hydro-
phobic molecule [90].
E5 and ER stress pathway
The presence of viral proteins may activate cellular
defence mechanisms and in particular the ER stress
response. 16E5 can suppress three key proteins of the
ER stress pathway: cyclooxygenase-2 (COX-2), XBP-1
and IRE1a. As it was suggested for other viruses, the
down-regulation of these proteins can favour viral per-
sistence [91] which is a major contributory factor to the
development of cancer by high-risk HPVs [92]. The
inhibition of the ER stress pathway by E5 seems to be
limited to the high risk types (Table 1); HPV-6b E5 is
unable to alter XBP-1 [93] and increased levels of COX-
2 were reported in recurrent respiratory papillomatosis
(RRP) lesions caused by low-risk HPV type 6b and 11
[94,95]. 16E5 is also able to lower COX-2 expression in
cells co-expressing E6/E7, suggesting that it might exert
similar activity during viral replication.
However, in different cell systems and clinical condi-
tions the same viral early genes seem to exert opposite
effects such as the induction of COX-2 expression in
spontaneously immortalized HaCaT and cervical cancer
lines C33A and SiHa [96,97]. It is possible that the dif-
ferent cell origin, immortalization and transformation
status, and the relative expression of the HPV early pro-
teins account for these contrasting data. Nevertheless
the reported consistent down-regulation of ER stress
response genes by 16E5 in primary genital keratinocytes
leads to speculation that this ER stress pathway inhibi-
tion is an event favourable to viral replication and per-
sistence [98].
Finally, 16E5 may induce expression of one of the
Prostaglandin E2 (PGE2) receptor in cervical cancer cells
by stimulating the binding of CREB to a variant CRE
site in the promoter of EP4 gene [99] (Figure 2). EP4
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pathway activates protein-kinase A which mediates ubi-
quitin-proteasome-mediated Bax degradation, inducing
antiapoptotic effects. Activation of EP4 by 16E5
increases anchorage-independent colony formation and
vascular endothelial growth factor (VEGF) expression,
leading to speculation that al least in some tumours E5
is involved in tumour growth, angiogenesis and metasta-
sis by inducing inflammatory cell signalling pathways.
HPV E5 and immune evasion
Cervical carcinogenesis is a multi-step process which
starts with viral infection; one of the steps is persistence
of viral infection. At least three major factors may
favour papillomavirus persistence: the virus life cycle
takes place away from dermal immune cells [100], the
virus does not cause cell lysis and therefore no or weak
inflammatory response [100], and, finally, the viral pro-
teins actively fight the immune response [101]. The E6
and E7 proteins play an important role in this fight but,
once again, the E5 protein seems to add help to the
virus by down-regulating MHC/HLA class I. MHC class
I is much reduced on the cell surface and accumulates
in the GA in cells expressing 16E5 [102]. The arrest of
MHC class I in the GA is due to E5-induced alkalinisa-
tion of the endomembrane compartments [103], follow-
ing 16E5-16 k subunit c interaction, and to the direct
interaction of E5 with the heavy chain of the MHC class
I complex [53,104]. These conclusions have been
reached in cultured HaCaT cells and W12 cell line, and
in vivo in the bovine model [105]. The functional effect
of the decreased expression of HLA is a reduction of
the recognition by CD8+ T cells in vitro [106].
Furthermore consistent with its role in the alkaliniza-
tion of endosomes, 16E5 can prevent the endosomal
breakdown of the invariant chain, a chaperone impor-
tant in the maturation of HLA class II, leading to inhibi-
tion of expression of surface HLA class II [107].
Inhibition of HLA class I transport by 16E5, in con-
trast to inhibition by BPV E5, is reversible by interferon
(IFN) treatment. IFN is sufficient to overcome the inhi-
bitory effect on MHC transport in presence of low levels
of 16E5. However, in oncogenic HPV infections, E6 and
E7 can inhibit the type I IFN pathway [108-110], thus
preventing the IFN-mediated release of E5-induced
blockage of HLA class I traffic.
Although an efficient mechanism to avoid cytoxic T
lymphocytes (CTL)-mediated immune clearance, the
reduction or absence of surface MHC class I renders
cells more susceptible to Natural Killer (NK) cell attack.
Human NK cells express multiple receptors that interact
with HLA class I molecules, including killer cell immu-
noglobulin-like receptors (KIRs) that predominantly
recognize classical HLA class I, including HLA-C, and
the C type lectin superfamily of receptors that
specifically interact with the nonclassical class I mole-
cule HLA-E. Recognition of the class I molecules by
their inhibitory receptors inhibits NK-mediated cell
lysis, which would occur in the absence of HLA-C/E.
Thus to efficiently evade immunosurveillance, HPV has
to selectively down-regulates the HLA class I molecules.
Indeed 16E5 selectively inhibits surface expression of
HLA-A and HLA-B without affecting either synthesis or
transport to the cell surface of HLA-C/E [97,100,101].
In this way HPV-16 is potentially capable of avoiding
both CTL and NK cell killing.
The bridging of innate and adaptive immune
responses can also be affected by E5 via the inhibition
of CD1d-mediated cytokine production that would
otherwise occurs upon interaction between cell surface
CD1d and iNKT cells [111].
It was reported that interactions between 16E5 and
calnexin interfere with modification of HLA class I HCs
and results in heavy-chain retention in the ER [51].
Since the synthetic pathways for CD1d and HLA class I
HCs are similar, this E5-calnexin interaction may alter
CD1d trafficking. Indeed, interactions between 16E5 and
calnexin do not appear to interrupt all of the functions
of calnexin, but just enough to coopt the cellular cytoso-
lic proteolytic pathway and degrade CD1d. Thus E5
inhibits the CD1d-mediated innate and adaptive
immune pathways early in HPV infection.
Finally, the reported novel association of HPV-16 and
HPV-31 E5 with Bap31 and A4 can also have an effect
on immune escape [52]. Bap31 is a chaperone involved
in quality control of, for instance, MHC molecules; A4
is a putative ion channel protein of the endoplasmic
reticulum. E5 and Bap31 physically interact and coloca-
lise in perinuclear structures and it was demonstrated
that this binding correlates with the ability to retain the
proliferative capacity of infected keratinocytes following
differentiation. E5 also binds and colocalises with A4
independently of Bap31, however the biological signifi-
cance of this interaction remains to be established.
Interestingly 16E5 first transmembrane domain which
binds MHC heavy chain shows homology with the third
transmembrane domain of Bap31 [53]. Therefore it is
possible that membrane-bound 16E5 displaces Bap31
from MHC I, maybe taking advantage of its own inter-
action with Bap31, and thus retains MHC I in the ER/
GA.
Thus immune escape mediated by E5 seems to be a
complex process, perhaps evolved to impact on different
pathways regulating the intracellular trafficking of
immunosurveillance molecules by general not-specific
mechanisms, such as endosomal alkalization, and speci-
fic ones, such as binding to MHC I heavy chain and
chaperones such as calnexin, invariant chain or Bap31.
It remains to be seen if E5 expression causes immune
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escape also in vivo. An inverse correlation exists
between expression of 16E5 and presence of surface
MHC I in the W12 keratinocyte line derived from a
CIN I biopsy [106], and in a small panel of naturally
occurring CIN lesions (Campo, unpublished observa-
tions). Additionally, again in a limited number of sam-
ples, an association has been reported between
decreased CD1d immunoreactivity and progression of
cervical neoplastic lesions with statistical significance (P
= 0.0001) [111].
Cell transformation pathways alternative to E5
Beta-HPVs do not code for an E5 protein. Considering
the ubiquitous presence of beta-HPVs in the healthy
population with almost no associated pathologies, the
lack of E5 ORF in these HPV could represent a factor
hampering the fully replicative cycle of these viruses.
Moreover, some beta-HPVs are detected together with
HPV-3 or related genotypes [112], and such a co-detec-
tion with E5-encoding HPVs suggests that beta-HPVs
benefit from E5 delivered by the co-infecting HPV
[113]. In human pathology there is a rare, autosomal
recessive genodermatosis associated with a high risk of
skin carcinoma, Epidermodysplasia Verruciformis (EV),
characterized by abnormal susceptibility to infection by
beta HPVs. Genetic analysis led to the identification of
two adjacent genes (EVER1 and EVER2), the mutation
of which segregates with the disease [114]. This extraor-
dinarily high sensitivity to infections by cutaneous beta-
HPVs in otherwise-healthy individuals carrying a muta-
tion in one of the EVER genes suggests that in humans
a natural EVER-based barrier exists, which protects the
host from PVs. The EVER proteins are crucial for the
functional integrity of the EVER/ZnT-1 complex
[115,116] responsible for maintaining a low level of free
zinc, modulating the activity of the AP-1 transcription
factors needed for viral genome expression. It has been
proposed that a cellular zinc imbalance constitutes an
important, perhaps even a crucial, step in the HPV life
cycle. It seems that breaking the barrier to cellular zinc
balance is an important element of the pathogenesis of
both alpha- and beta-HPVs, and the main difference
between these two groups would be a mechanism
employed to achieve the same goal. Beta-HPVs are
defective for this zinc imbalance, an important growth-
promoting function performed by E5 of alpha-HPVs,
and inactivation of EVER proteins may compensate for
the missing viral function [117]. Indeed the transmem-
brane viral 16E5 and cellular EVER proteins interact
both with the zinc transporter ZnT1, and are likely to
modulate zinc homeostasis [115,117]. The disruption of
the cellular zinc-transporting complex achieved during
the long co-evolution of HPV and the human species by
two completely unrelated strategies underlines the
general importance of the cellular zinc (im)balance in
the papillomavirus life cycle and the central role played
by E5.
In the absence of E5, beta-papillomaviruses have
evolved a mechanism to escape immunosurveillance
independent of E5. Indeed the E6 and E7 oncoproteins
of cutaneous HPV-38 interfere with the interferon path-
way. Expression of the two viral proteins in HaCaT ker-
atinocytes led to a decrease of MHC I levels. This
down-regulation was associated with a reduction of
expression of MHC I heavy chain, of the peptide cha-
perone TAP and of the STAT-1 downstream effector
IRF-1 [118]. Thus, at least for some (high risk?) beta
papillomavirus other E5-unrelated mechanisms take part
in the process of viral replication and avoidance of
immune control.
HPV E5 and carcinogenesis
HPV E5 proteins are not thought to play a role in the
later steps of malignant progression because in high-risk
HPV infections that progress to cancer the viral DNA
typically integrates into the host genome often resulting
in the loss of the E2 and E5 genes [65]. However in con-
trast to other high-risk HPVs, HPV-16 DNA can exist in
integrated, episomal or integrated and episomal form in
malignant lesions of the cervix. In one study about 60%
of HPV-16-positive cervical cancer expressed the 16E5
protein [28] and recent reports suggest that these
tumours with episomal HPV-16 may have a more
aggressive behaviour (Venuti, unpublished data). Never-
theless, the fact that a substantial proportion of the
tumours do not express E5 indicates that the protein is
not essential for HPV-16 mediated tumour progression.
Although 16E5 may not contribute to malignant pro-
gression, there is evidence that if E5 expression proceeds
beyond early lesional stages, keratinocyte differentiation
and immunological removal of infected cells does not
take place increasing the likelihood of subsequent onco-
genic transformation.
The presence of an E5 gene in all HR HPVs [23] and
the detection of E5 variants with higher codon usage in
high grade lesions [119] point to an important role of
E5 during PV-induced pathogenesis. This assumption is
further strengthen by studies on transgenic animals: (a)
Transgenic mice expressing only HPV-16 E6 and E7
oncogenes in the basal epithelium develop fewer
tumours than those arising in transgenic mice expres-
sing HPV-16 E5, E6 and E7 genes [120] (b) Mice trans-
genic for 16E5 (without HPV 16 E6 and E7) develop
skin tumours with high frequency [67].
One or more of the demonstrated biological activities
of 16E5 may be responsible for early post-infection
events enhancing the probability of subsequent carcino-
genesis. Indeed viral persistence is considered to be an
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important factor in the neoplastic progression of a pre-
malignant lesion [65]. The 16E5-induced down regula-
tion of MCH I [104] and MHC II [107], resulting in the
infected cell evading immunosurveillance, may increase
the duration and size of the HPV infection raising the
probability that some infected cells will become trans-
formed. The expansion of infected cells may also be
favoured by 16E5-induced DNA synthesis in differentiat-
ing keratinocytes [121] and by 16E5-enhanced ligand-
dependent activation of EGF-R [56,58-60]. Furthermore
the ability of 16E5 to inhibit gap-junction-mediated
intercellular communication via connexin 43 interaction
may render the infected cells more insensitive to
homeostatic growth control signals from adjacent, non-
infected cells [83,84]. 16E5 induction of cell fusion may
represent another critical event in the early stage of
HPV-associated cervical cancer [41-43]. Thus, HR HPVs
E5 is involved in the very early stage of carcinogenesis
by prolonging the life and expanding the pool of the
infected cells from which cancer may arise as a stochas-
tic event. Finally E5 can be also involved in negative
selection of cells harboring episomal virus and in turn
favoring the selection of cells with integrated virus. Epi-
some loss, associated with induction of antiviral
response genes, could be a key event in the spontaneous
selection of cervical keratinocytes containing integrated
HPV16. Microarray analysis showed that episome loss
was closely associated with endogenous activation of
antiviral response genes that are also inducible by type I
IFN pathway [122]. Recently this activation of the anti-
viral state was shown to be induced by 16E5 through
the stimulation of IRF-1 and IFN-b [123]. In this sce-
nario cervical carcinogenesis requires not only HR HPV
integration, but also loss of inhibitory (E2 expression)
episomes by the E5-induced establishment of an anti-
viral state that may accelerate episomal clearance.
BPV E5
BPV E5 is the best characterized of the E5 proteins and
has provided the blueprint for investigations into HPV
E5. E5 is the major BPV oncoprotein, only 44 amino
acid in BPV type 1 (BPV-1) and 42 in BPV type 4 (BPV-
4) [124-127]. Both proteins can be divided into two dis-
tinct domain: an amino-terminal domain which makes
up the majority of the protein and consists of strongly
hydrophobic leucine-rich membrane-spanning amino
acid residues with a single hydrophilic amino acid at
position 17 (glutamine in BPV-1 E5 and asparagine in
BPV-4 E5), and a short hydrophilic carboxyl-terminal
domain[125,128]. Both E5 proteins localize in the endo-
membrane compartments of the GA, ER and plasma
membrane. It has been suggested for BPV-1 E5 that
helix-helix hydrophobic contacts within the TM domain
play a critical role in functional dimer assembly and that
the cystein-containing motif functions as additional
dimer stabilization [129-131].
Cell transformation by BPV E5
Despite their structural similarity, BPV-1 and BPV-4 E5
differ in the ways they achieve cell transformation, likely
reflecting the different origin of the cells hosting the
two viruses. BPV-1 infects fibroblasts and skin keratino-
cytes giving rise to fibropapillomas, whereas BPV-4
infects solely the epithelial cells of the mucous epithe-
lium of the upper gastrointestinal tract [132]. Thus,
while expression of BPV-1 E5 by itself is sufficient to
fully transform mouse and primary human fibroblast
cells [133,134], BPV-4 E5 contributes to the transformed
phenotype of primary cells by conferring anchorage
independent growth, growth in low serum, focus forma-
tion and increased cell motility but only in the presence
of the other viral oncoproteins, resembling in this
respect 16E5 (Table 1) [127,135,136]. For both proteins
the hydrophobic domain, the hydrophilic residues at
position 17 and the hydrophilic C-terminal tail are criti-
cal for their transforming activities [135,137].
BPV-1 E5 induces tumourigenic cell transformation by
strongly and specifically binding to its cellular target,
Platelet Derived Growth Factor Receptor b receptor
(PDGFb-R) tyrosine kinase in a ligand-independent
manner [138-141]. The PDGFb-R is a transmembrane
protein which is normally activated by binding of its
ligand PDGF. BPV-1 E5 can bind as a dimer to two
monomers of the PDGFb-R [140,142,143], inducing
receptor dimerisation which in turn causes trans-phos-
phyorylation of specific tyrosine kinase residues within
the cytoplasmic domain of the receptor resulting in
mitogenic signalling [144]. Studies using PDGFb-R
kinase inhibitors show that maintenance of transforma-
tion by BPV-1 E5 requires sustained PDGFb-R activa-
tion [145,146].
BPV-1 E5 interacts with the PDGFb-R via its trans-
membrane domain [141,142,147], unlike the natural
ligand PDGF which binds the receptor via its ligand
binding domain Extensive characterisation of E5 demon-
strates that there are essentially four residues important
for PDGFb-R binding and activation. These are the
transmembrane glutamine (Gln17) important for both
dimerisation of E5 and for its interaction with PDGFb-
R; the aspartic acid (Asp 33) residue at the juxtamem-
brane region which provides a negative charge required
for receptor interaction and two terminal cysteine resi-
dues (Cys37, Cys39) essential for homodimerisation of
E5 [125,137,145,148,149]. Interestingly, these four resi-
dues are conserved among the E5 proteins of fibropapil-
lomaviruses [150] whereas other residues within the
transmembrane region are less well conserved. Muta-
genesis studies have demonstrated that BPV-1 E5 can
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tolerate a surprising number of mutations and that the
maintenance of the hydrophobic nature of E5 and the
conserved residues is enough to confer transforming
activity [151-155].
Mutational analyses of the receptor itself have identi-
fied key residues important for function. The PDGFb-R
is as single span type I transmembrane receptor with
three domains: an amino terminal domain which binds
its receptor, a short membrane spanning region and an
intracellular kinase domain. Two residues appear to be
important for E5 interaction and transformation activity:
a threonine 513 in the transmembrane domain is
required for H bonding with Gln17 residue of the E5
protein and lysine at 499 in the juxtamembrane region
with Asp33 in the E5 protein [156-158]. An important
feature of BPV-1 E5 mediated PDGFb-R activation is
that activation occurs independently of PDGF since E5
can constitutively activate PDGFb-R deletion mutants
that lack the extracellular ligand-binding domain
[141,159].
The interaction between BPV-1 E5 and PDGFb-R is
highly specific. At physiological levels, E5 is able to
interact with PDGFb-R but not with other tyrosine
kinase receptors including insulin receptors, basic fibro-
blast growth factor receptor or insulin-like growth factor
receptors, however at higher levels E5 can interact with
additional receptors [140,144]. E5 cannot bind the
PDGF a receptor, a closely related receptor to the
PDGFb-R whilst both of these receptors can be activated
by PDGF [140-144]. The specificity is thought to be
conferred by the transmembrane domain [159].
Most of the studies on BPV E5 and PDGFb-R activa-
tion have been performed in vitro. Borzacchiello et al
(2006) have shown that BPV-2 E5 interacts with and
activates the PDGFb-R in vivo in bovine urinary bladder
cancers (Figure 3). Moreover, the binding of E5 to
PDGFb-R induces the activation of different signal
transduction pathways: PDGFb-R and phosphoinositide
3 kinase (PI3K) physically interact as do PDGFb-R and
the Grb2-Sos complex. PI3K-Akt and Grb2-Sos-Ras sig-
nals are all potentiated in cancer, but, as in in vitro
models, the levels of Erk and Mek proteins are not sig-
nificantly overexpressed [160-162] (Figure 4). BPV E5 is
able to activate c-src, a non receptor tyr kinase, but not
the closely related c-Fyn and PI3K [163]. The activation
of the latter is necessary but not sufficient to induce cell
transformation independently of PDGFb-R signalling
[163,164]. Unlike BPV-1 E5, BPV-4 E5 induces transfor-
mation of established cells independently from the con-
stitutive activation of tyrosine kinase growth receptors
(Table 1) [165]. Cell transformation by BPV-4 E5 (either
of established cells by itself or of primary cells in co-
operation with other viral oncoproteins) is achieved
through transactivation of the cyclin A gene promoter,
increased cyclin A expression and cyclin A-associated
kinase activity, and inhibition of the negative regulator
of cell cycle, p27Kip1 [135,166-168]. Mutational analyses
of BPV-4 E5 have demonstrate that, as is the case for
BPV-1 E5, the residue at position 17 and the hydrophilic
C-terminal tail are critical for its transforming activities
[135]. Thus both mutation of Asp 17 and deletion of
the C-terminus hydrophilic domain completely abrogate
cell transformation and E5 ability to activate the cyclin
A pathway [135].
Down-regulation of MHC expression
The down-regulation of surface MHC I and retention of
the MHC I complex in the GA were first shown in cells
expressing BPV-4 E5 [169] and then confirmed for
other E5 proteins both from BPV and HPV. BPV E5
interferes with MHC I biosynthesis at multiple steps:
transcriptional inhibition of the MHC class I heavy
chain gene, degradation of the heavy chain and physical
interaction with any residual heavy chain [169,170].
Only the physical interaction with heavy chain is shared
with 16E5 [99]. Moreover, in the case of BPV-4 E5 the
down-regulation of surface MHC I is irreversible, as
interferon cannot restore the transport of the MHC I
complex to the cell surface [128], while this is not the
case for 16E5. This may reflect the fact that E5 is a
“stronger” protein in BPV than in HPV.
In any event, the finding of MHC down-regulation by
E5 has proved of great importance since it defined a
new biological activity shared by both BPV and HPV E5
(Table 1), which allows the infected cell not to be effec-
tively recognised by cytotoxic CTL [106].
BPV E5: other biological activities
BPV E5 interacts with the 16 kDa protein, a component
of the V-ATPase [147,171]. In the case of BPV-1 E5,
this protein association exists as a tri-component com-
plex, which contains also PDGFb-R molecules. Muta-
tional analyses have demonstrated that glutamic acid
143 in the transmembrane domain of the 16 kDa pro-
tein and glutamine 17 in the transmembrane domain of
BPV-1 E5 are essential for E5-16 kDa stable association
[172]. The binding of the E5 with 16 kDa perturbs the
correct assembly of V-ATPase and H+ pumping, with
persistent alkalinization of the GA and endosomal vesi-
cles [103] and may lead, directly or indirectly, to a
marked loss of cell-cell communication through down-
regulation of gap junctions (Table 1) [101,173], render-
ing the transformed cells more insensitive to homeo-
static growth control signals from adjacent normal cells.
However, in the case of HPV-16 inhibition of gap junc-
tion intercellular communication has been attributed to
the interaction of E5 with connexin 43 [84]. E5-expres-
sing bovine urinary bladder tumours show activated
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calpain 3, suggesting a possible involvement of this pro-
tein in urothelial carcinogenesis [174].
Targeting HPV-16 E5 for cervical treatment
16E5 activates many different cellular pathways involved
mostly in the early stage of cervical carcinogenesis
[175]. Different studies have pointed out the possibility
of E5 targeting for CaCx therapy. In animal studies,
16E5 delivered by an adenovirus vector reduces the
growth of tumours and the E5 vaccine induces protec-
tion against tumours through CD8+ cytotoxic T cells
(CTLs) [176]. The same research group has further
Figure 3 BPV E5 and PDGFb-receptor co-precipitate and co-localize in bovine urinary bladder carcinoma. A. Co-immunoprecipitation of
the PDGFb-receptor with E5 antiserum. Tissue lysates were immunoprecipitated with the anti E5 antibody and the immunoblot was analyzed
with the anti- PDGFb-receptor antibody. Lanes 1-3 are BPV-2 positive bovine urinary bladder cancer samples, T1, T2, T3. Lane 4 is BPV-2 DNA
positive normal bovine bladder mucosa, N1. B. Coimmunoprecipitation of the E5 oncoprotein with the PDGFb-receptor antiserum. The arrow
indicates the E5 oncoprotein and its estimated kDa weight. In a parallel blot, the same amount of lysate was probed with an antibody to b-actin
to control for the quantity of protein (bottom panel) C. Colocalization (yellow) of PDGFb-receptor (red) and E5 (green) in bovine neoplastic
urothelium. The white arrows indicate a juxtanuclear position of E5 and PDGFb-receptor (reproduced with permission from Borzacchiello et al.,
Oncogene 2006).
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demonstrated that the stimulating epitope was an E5
peptide (aminoacids 25-33) and vaccination with this
peptide carrying CpG oligonucleotides reduced tumour
growth [177]. 16E5 modulates different cellular path-
ways and the targeting of these relevant pathways may
lead in a near future to a possible therapeutic approach.
In addition, E5 is more consistently expressed in the
early stage of viral infection and in precancerous lesions
[178], and therefore E5 or E5 altered pathways could be
targeted to cure the infection and to prevent precancer-
ous lesions from progressing into invasive cancers. 16E5
interacts with many different pathways including upre-
gulation of growth factor signalling, induction of inflam-
matory cell signalling, angiogenesis and antiapoptosis
(Figure 2). Furthermore E5 participates in malignant
transformation by supplementing (added value) the roles
of E6 and E7. All these E5-induced signalling pathways
(Figure 2) or E5 itself can be addressed by therapies
already utilised against the other HPV oncogenes such
as radioimmunotherapy, oncolytic adenoviruses [179],
gene silencing using short interfering RNA (siRNA)
[180] and others, which have been originally used to tar-
get the E5-upregulated pathways. EGF-R, COX-2 or ET1
inhibitors should be useful in controlling E5 activity in
the precancerous lesions as well as other small mole-
cules interfering with downstream molecules. Finally, E5
may be considered a viroporin, like the VP4 of SV40
[181] and, therefore, susceptible of therapy by com-
pounds that affect similar structures produced by other
viruses. Indeed amantidine, amiloride, long-alkyl-chain
iminosugar derivatives and new compounds seem to
affect, to various extent, the activity of the 16E5 protein
in vitro (A. Macdonald, personal communication, 11
DNA TV Meeting, Trieste, Italy, 2011)
Conclusions
The main activities of E5 can be resumed as follows:
Although E6 and E7 provide the primary transforming
activities of HR HPVs, E5 can augment their function
and contribute to tumour progression:
Figure 4 Model of cellular events during cell transformation mediated by BPV-1 E5. E5 binds to the transmembrane domain of PDGFb-R
and induces receptor dimerisation and autophosphorylation. The activated receptor can recruit p85-PI3K that activates the AKT and JNK
pathway. PDGFbR stimulation of a PI3K-AKTpathway leads to increased expression of cyclin D3. Recruitment of Sos1-GRB2 complex to p-PDGFbR
may activate Ras, although the downstream MAPK pathway is not activated; therefore Ras may activate PI3-K pathway. The SHP2-p66Shc
complex bound to the activated PDGFb-R may be recruited and inactivates p190BRhoGAP, resulting in activation of a Rho family GTPase, Rho A
and its downstream effector ROCK inducing focus formation. E5 is able to interact with c-src in late endosomal and trans-Golgi compartment,
thus resulting in c-src constitutively activation. E5 interacts with the C-terminus of MHC I heavy chain and causes the retention of MHC I in the
Golgi apparatus, thus preventing its transport to the cell surface. E5 perturbs the physiological activity of the V-ATPase by inhibiting the correct
assembly of V-ATPase and H+ pumping, thus inducing persistent alkalinization of the Golgi and endosomes vescicles.
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When expressed alone, HPV E5 has weak transform-
ing activity.
In transgenic mouse models, 16E5 expression in the
skin produces epithelial hyperproliferation with sponta-
neous tumour formation, whereas in estrogen-treated
mice, expression of E5 alone can induce cancers [182],
suggesting a role for E5 as a true oncoprotein.
The presence in HPV 16-positive cervical tumours of
viral episomes in addition to viral integrants leads to the
hypothesis that there are multiple pathways to HPV
induced tumourigenesis see above. Beside the basic
hypothesis of high-level expression of E6 and E7 conse-
quent to the abrogation of the repressive effects of E2
due to the loss of the E2 gene during integration,
another pathway can be active in cells that still maintain
viral episomes, in which E5 would augment the activity
of E6 and E7. The expression of E5 is increased on dif-
ferentiation to promote proliferation of differentiated
cells and productive viral replication.
The localization of HPV E5 to the endoplasmic reticu-
lum suggests its activity may be related to the trafficking
of cytoplasmic membrane proteins through this cellular
compartment, in particular of growth factor receptors
and of molecules involved in immune control.
There are multiple documented intracellular binding
targets for 16E5 such as the EGF receptor family mem-
ber ErbB4 [77], the 16-kDa subunit of the vacuolar H
+-ATPase [39,55], the heavy chain of HLA type I [104],
calnexin [51], the zinc transporter ZnT-1, the EVER1
and EVER2 transmembrane channel-like proteins
[115,117] the nuclear import receptor family member
KNb3 [45], BAP31 and A4 [44,52] (Figure 2).
However the role of 16E5 in carcinogenesis seems to
be limited to the early stages of cervical carcinogenesis
because the E5 gene is frequently deleted when the
HPV genome is integrated during malignant progression
[28,68,183]. Nevertheless, the expression of 16E5 as
detected by immunohistochemistry, was reported in
approximately 80, 90 and 60% of HPV 16-infected
LSILs, high-grade SILs and cervical carcinomas, respec-
tively [28]. Furthermore data from a limited number of
patients were presented at the 1st International Work-
shop on E5 Oncogene [184] suggesting that E5 expres-
sion may lead to a worse response to treatment with
taxanes (Venuti, unpublished data). Therefore, targeting
E5 which is frequently expressed in earlier stages of
malignant transformation may be a rational approach
for preventing premalignant lesions from progressing
into invasive cervical cancers [175]. The recent success-
ful eradication of HPV-induced tumours in mice by
anti-E5 vaccination [176] indicates that E5 can be used
in immunotherapy. The neutralization of E5 or of E5-
induced signalling pathways, therefore, whether immu-
nological or chemical, could be advantageous
particularly in HPV infections and pre-cancerous lesions
where there are no treatments available.
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